Importantly from a therapeutic perspective, MTHFD2 down-regulation sensitized RCC cells to anti-folate chemotherapy drugs, such as methotrexate (MTX) and fluorouracil (5-FU). Here, MTHFD2 is linked to renal cell carcinoma.